73 research outputs found
Journal Staff
Primary Immunodeficiencies (PID) are genetically inherited disorders characterized by defects of the immune system, leading to increased susceptibility to infection. Due to the variety of clinical symptoms and the complexity of current diagnostic procedures, accurate diagnosis of PID is often difficult in daily clinical practice. Thanks to the advent of "next generation'' sequencing technologies and target enrichment methods, the development of multiplex diagnostic assays is now possible. In this study, we applied a selector-based target enrichment assay to detect disease-causing mutations in 179 known PID genes. The usefulness of this assay for molecular diagnosis of PID was investigated by sequencing DNA from 33 patients, 18 of which had at least one known causal mutation at the onset of the experiment. We were able to identify the disease causing mutations in 60% of the investigated patients, indicating that the majority of PID cases could be resolved using a targeted sequencing approach. Causal mutations identified in the unknown patient samples were located in STAT3, IGLL1, RNF168 and PGM3. Based on our results, we propose a stepwise approach for PID diagnostics, involving targeted resequencing, followed by whole transcriptome and/or whole genome sequencing if causative variants are not found in the targeted exons
New insights in the use of immunoglobulins for the management of immune deficiency (PID) patients
Immunoglobulin replacement therapy (IRT) is standard treatment for patients with primary immunodeficiency
(PID). Because most of the patients with PID will require long life-time immunoglobulin replacement therapy,
the quality of the prescribed products is of utmost importance. The IRT is generally administered either intravenously
(abbreviated IVIG), or subcutaneously (abbreviated SCIG). Both routes have been demonstrated to be effective.
The preferred route may vary at different times during a given patient’s life. Options are therefore not fixed and the
choice of route for immunoglobulin therapy will depend on several factors, including patient characteristics, clinical
indication, venous access, side effects, rural or remote location, treatment compliance and patient preference.
Many years ago, immunoglobulin therapy was associated with side effects which may compromise patient’s compliance
and quality of life of the patients. Most of the side effects were related to impurities. Recently, major advances
in the manufacturing process have been made and new processes, such as the Quality by design (QbD) approach
were added into the manufacturing steps to ensure patients tolerability and safety. Due to the improved purity of
the immunoglobulin products obtained by these processes, the incidence of side effects is lower, while the ways
of administration of Ig therapy and the choice of the regimen has widened to suit patient’s preference and needs
Chronic granulomatous disease recognised in 42-years-old patient
Przewlekła choroba ziarniniakowa (PChZ) jest heterogenną grupą chorób związanych z defektem enzymu oksydazy NADPH
odpowiedzialnej za produkcję nadtlenków przez granulocyty obojętnochłonne, których brak lub niedobór uniemożliwia zabijanie
sfagocytowanych przez nie drobnoustrojów. Typowymi objawami PChZ są bakteryjne lub grzybicze nawracające ciężkie,
często zagrażające życiu infekcje głównie płuc, skóry, węzłów chłonnych oraz przewodu pokarmowego (wątroby). Rozpoznanie
jest ustalane na podstawie wywiadów, objawów oraz testów wykazujących upośledzoną funkcję fagocytozy granulocytów
(testy NBT, RDH czy bezpośrednie testy, których wynik wskazuje na deficyt produkcji nadtlenków). Objawy występują
zwykle w pierwszych latach życia, prowadzą często do zgonu w 2. lub 3. dekadzie. Poniżej przedstawiono przypadek
chorej, u której rozpoznanie PChZ ustalono dopiero w 42. roku życia.Chronic granulomatous disease (CGD) comprises a heterogeneous group of diseases that are caused by defect in the
superoxide-producing NADPH oxidase of neutrophils. This defect impairs the intracellular killing of microorganisms. Typical
manifestations are recurrent bacterial or mycotic infections affecting the lungs, skin, lymph nodes and gastrointestinal tract
(liver). Chronic granulomatous disease could be diagnosed on the basis of the anamnesis, clinical picture and results of
granulocyte function tests showing impaired phagocytic activity (NBT tests, RDH test and a deficit of superoxide production).
Typically symptoms of disease occur in the first years of live, leading often to death in the 2. or 3. decade. Below we
present a patient, in whom diagnosis of the CGD was established at the age of 42
New insights in the use of immunoglobulins for the management of immune deficiency (PID) patients
Immunoglobulin replacement therapy (IRT) is standard treatment for patients with primary immunodeficiency
(PID). Because most of the patients with PID will require long life-time immunoglobulin replacement therapy,
the quality of the prescribed products is of utmost importance. The IRT is generally administered either intravenously
(abbreviated IVIG), or subcutaneously (abbreviated SCIG). Both routes have been demonstrated to be effective.
The preferred route may vary at different times during a given patient’s life. Options are therefore not fixed and the
choice of route for immunoglobulin therapy will depend on several factors, including patient characteristics, clinical
indication, venous access, side effects, rural or remote location, treatment compliance and patient preference.
Many years ago, immunoglobulin therapy was associated with side effects which may compromise patient’s compliance
and quality of life of the patients. Most of the side effects were related to impurities. Recently, major advances
in the manufacturing process have been made and new processes, such as the Quality by design (QbD) approach
were added into the manufacturing steps to ensure patients tolerability and safety. Due to the improved purity of
the immunoglobulin products obtained by these processes, the incidence of side effects is lower, while the ways
of administration of Ig therapy and the choice of the regimen has widened to suit patient’s preference and needs
Chronic granulomatous disease: the European experience.
CGD is an immunodeficiency caused by deletions or mutations in genes that encode subunits of the leukocyte NADPH oxidase complex. Normally, assembly of the NADPH oxidase complex in phagosomes of certain phagocytic cells leads to a "respiratory burst", essential for the clearance of phagocytosed micro-organisms. CGD patients lack this mechanism, which leads to life-threatening infections and granuloma formation. However, a clear picture of the clinical course of CGD is hampered by its low prevalence (approximately 1:250,000). Therefore, extensive clinical data from 429 European patients were collected and analyzed. Of these patients 351 were males and 78 were females. X-linked (XL) CGD (gp91(phox) deficient) accounted for 67% of the cases, autosomal recessive (AR) inheritance for 33%. AR-CGD was diagnosed later in life, and the mean survival time was significantly better in AR patients (49.6 years) than in XL CGD (37.8 years), suggesting a milder disease course in AR patients. The disease manifested itself most frequently in the lungs (66% of patients), skin (53%), lymph nodes (50%), gastrointestinal tract (48%) and liver (32%). The most frequently cultured micro-organisms per episode were Staphylococcus aureus (30%), Aspergillus spp. (26%), and Salmonella spp. (16%). Surprisingly, Pseudomonas spp. (2%) and Burkholderia cepacia (<1%) were found only sporadically. Lesions induced by inoculation with BCG occurred in 8% of the patients. Only 71% of the patients received antibiotic maintenance therapy, and 53% antifungal prophylaxis. 33% were treated with gamma-interferon. 24 patients (6%) had received a stem cell transplantation. The most prominent reason of death was pneumonia and pulmonary abscess (18/84 cases), septicemia (16/84) and brain abscess (4/84). These data provide further insight in the clinical course of CGD in Europe and hopefully can help to increase awareness and optimize the treatment of these patients
National experience with adenosine deaminase deficiency related SCID in Polish children
IntroductionDeficiency of adenosine deaminase (ADA) manifests as severe combined immunodeficiency (SCID), caused by accumulation of toxic purine degradation by-products. Untreated patients develop immune and non-immune symptoms with fatal clinical course. According to ESID and EBMT recommendations enzyme replacement therapy (ERT) should be implemented as soon as possible to stabilize the patient’s general condition, normalize transaminases, treat pulmonary proteinosis, bone dysplasia, and protect from neurological damage. Hematopoietic stem cell transplantation (HSCT) from a matched related donor (MRD) is a treatment of choice. In absence of such donor, gene therapy (GT) should be considered. HSCT from a matched unrelated donor (MUD) and haploidentical hematopoietic stem cell transplantation (hHSCT) are associated with worse prognosis.Material and methodsWe retrospectively evaluated the clinical course and results of biochemical, immunological and genetic tests of 7 patients diagnosed in Poland with ADA deficiency since 2010 to 2022.ResultsAll patients demonstrated lymphopenia affecting of T, B and NK cells. Diagnosis was made on the basis of ADA activity in red blood cells and/or genetic testing. Patients manifested with various non-immunological symptoms including: lung proteinosis, skeletal dysplasia, liver dysfunction, atypical hemolytic-uremic syndrome, and psychomotor development disorders. Five patients underwent successful HSCT: 3 patients from matched unrelated donor, 2 from matched sibling donor, and 1 haploidentical from a parental donor. In 4 patients HSCT was preceded by enzyme therapy (lasting from 2 to 5 months). One patient with multiple organ failure died shortly after admission, before the diagnosis was confirmed. None of the patients had undergone gene therapy.ConclusionsIt is important to diagnose ADA SCID as early as possible, before irreversible multi-organ failure occurs. In Poland HSCT are performed according to international immunological societies recommendations, while ERT and GT are less accessible. Implementation of Newborn Screening (NBS) for SCID in Poland could enable recognition of SCID, including ADA-SCID
Interstitial lung disease in children with selected primary immunodeficiency disorders-a multicenter observational study
- …